Evidence map›Paper›PMID 42578117›Full record

ArticleInflammatory intestinal diseases

Balloon-Assisted Enteroscopy Assesses Endoscopic Remission and Mucosal Healing following Risankizumab Initiation in Crohn's Disease.

Shinya Yoshida, Atsushi Nishida, Yoshihiro Yokota, Takayuki Imai, Masashi Ohno, Takuji Iwashita

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Inflammatory intestinal diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shinya YoshidaDepartment of Medicine, Shiga University of Medical Science, Otsu, Japan.
Atsushi NishidaDepartment of Medicine, Shiga University of Medical Science, Otsu, Japan.
Yoshihiro YokotaDepartment of Medicine, Shiga University of Medical Science, Otsu, Japan.
Takayuki ImaiDepartment of Medicine, Shiga University of Medical Science, Otsu, Japan.
Masashi OhnoDepartment of Medicine, Shiga University of Medical Science, Otsu, Japan.
Takuji IwashitaDepartment of Medicine, Shiga University of Medical Science, Otsu, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Endoscopic control of inflammation is a key treatment goal in Crohn's disease. However, real-world endoscopic outcomes of risankizumab assessed by paired balloon-assisted enteroscopy (BAE) remain limited. We examined endoscopic outcomes at the visit closest to week 52 after risankizumab initiation using paired BAE. Methods: We retrospectively studied adults with Crohn's disease who initiated risankizumab. The primary analysis set comprised 42 patients who underwent BAE at baseline and at the visit closest to week 52. Endoscopic activity was quantified using the Simple Endoscopic Score for Crohn's Disease (SES-CD). Endoscopic remission was defined as SES-CD ≤4 with a decrease of ≥2 points from baseline, and mucosal healing was defined as SES-CD ≤2. Results: In the paired BAE cohort ( Conclusion: In this real-world Japanese cohort, risankizumab was associated with significant endoscopic improvement assessed by paired BAE at follow-up. Endoscopic remission and mucosal healing rates were high in the paired BAE cohort, particularly for endoscopic remission among bio-naïve patients.

Indexed as

Balloon-assisted enteroscopyCrohn’s diseaseEndoscopic remissionMucosal healingRisankizumab

Identifiers

PMID42578117
PMCPMC13456675

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.